论文部分内容阅读
目的:探讨福辛普利联合通心络胶囊对心衰患者心功能及IL-17、CRP水平的影响。方法:108例心力衰竭患者(CHF)依据随机数字表法分为两组:对照组采用福辛普利治疗,观察组采用福辛普利联合通心络胶囊治疗,比较两组患者治疗前后心功能和细胞因子水平变化。结果:观察组治疗总有效率(51例,94.4%)显著高于对照组(41例,75.9%)(x~2=7.34,P=0.01);两组患者治疗后各项心功能指标(LVESV、LVEDD、LVEF、CO、CI、SV、LVMI)较治疗前显著改善(P<0.05),但观察组治疗后LVESV、LVEDD、LVEF、CO、CI、SV值显著优于对照组,差异显著(P<0.05);心衰患者经治疗之后BNP、IL-17和CRP均显著下降,但观察组治疗后各细胞因子水平显著低于对照组(P<0.05);观察组与对照组不良反应率(11.1%与14.8%)无统计学差异(P>0.05)。结论:福辛普利联合通心络胶囊能够有效改善患者心功能,降低血清IL-17和CRP水平,具有较好的治疗效果。
Objective: To investigate the effects of fosinopril combined with Tongxinluo capsule on cardiac function and the levels of IL-17 and CRP in patients with heart failure. Methods: 108 patients with heart failure (CHF) were divided into two groups according to the random number table: the control group was treated with fosinopril, the observation group was treated with fosinopril combined with Tongxinluo capsule, the two groups were compared before and after treatment Changes in function and cytokine levels. Results: The total effective rate of treatment group (51 cases, 94.4%) was significantly higher than that of control group (41 cases, 75.9%) (x 2 = 7.34, P = 0.01) LVESV, LVEDD, LVEF, CO, CI, SV, LVMI) were significantly improved (P <0.05), but the LVESV, LVEDD, LVEF, CO, CI and SV in the observation group were significantly better than those in the control group (P <0.05). The levels of BNP, IL-17 and CRP in patients with heart failure after treatment were significantly decreased, but the levels of cytokines in the observation group were significantly lower than those in the control group (P <0.05). The adverse reactions of the observation group and the control group Rates (11.1% vs 14.8%) showed no significant difference (P> 0.05). CONCLUSION: Fosinopril combined with Tongxinluo capsule can effectively improve the cardiac function, reduce the level of serum IL-17 and CRP, and has a good therapeutic effect.